AdvaCare is a GMP manufacturer of Clomifen Citrate tablets.
Clomiphene citrate has been demonstrated to be a useful therapy for an ovulatory patient desiring pregnancy. Clomiphene citrate is capable of interacting with estrogen-receptor-containing tissues, including the hypothalamus, pituitary, ovary, endometrium, vagina, and cervix.
It may compete with estrogen for estrogen-receptor-binding sites and may delay replenishment of intracellular estrogen receptors. Clomiphene citrate initiates a series of endocrine events culminating in a preovulatory gonadotropin surge and subsequent follicular rupture.
The first endocrine event in response to a course of clomiphene therapy is an increase in the release of pituitary gonadotropins. This initiates steroidogenesis and folliculogenesis, resulting in growth of the ovarian follicle and an increase in the circulating level of estradiol. Following ovulation, plasma progesterone and estradiol rise and fall as they would in a normal ovulatory cycle.
As with all pharmaceuticals, some unwanted effects can occur from the use of clomifene citrate. Always consult a doctor or health care professional for medical advice before use. Common side effects occur most likely at higher doses and with long-term treatment including symptom, but may not be limited to swelling of ovaries, flushing, stomach discomfort, dizziness, insomnia, lightheadedness, fatigue, depression, blurred vision, skin rash, allergic reaction with swelling, breathlessness, changes in skin pigment. Seek medical attention if the following develop: hair loss, cataracts, fainting, mood changes, speech changes, and fits.
For a comprehensive list of all possible effects, consult your doctor.
If any symptom persists or gets worse, or you notice any other symptom, then please call your doctor immediately.